followup windows in pivotal trials commonly ranged from ~12 weeks to 72 weeks, with many key results at 2652 weeks
However, the results of these types of studies, which are briefly described below, are not clearly established and await replication
Michele Green has been expertly treating patients in her Upper East Side, New York City, office for more than 25 years
Association of prenatal maternal anemia with neurodevelopmental disorders
Very common (10% of patients) Nausea peaks during titration, typically subsides within 48 weeks at a stable dose Vomiting, diarrhoea, constipation Abdominal pain or discomfort Reduced appetite (this is the therapeutic effect, not an adverse effect) Less common but serious stop and see a doctor Severe, persistent abdominal pain radiating to the back possible pancreatitis Right upper abdomen pain, fever, yellowing possible gallstones / gallbladder disease Persistent neck lump, hoarseness, difficulty swallowing evaluate thyroid Rapid heartbeat, severe dehydration from vomiting Hypoglycaemia when semaglutide is combined with insulin or sulfonylureas What the Indian data shows: a 2025 study of Indian patients found GI side effects are the leading cause of discontinuation, peaking during dose escalation
While it offers significant benefits, being aware of its side effects, including the possibility of developing a rash, is crucial for users
